Dr. Reddy's Laboratories announces acquisitionof ANDA portfolio


Hyderabad, India and Princeton, NJ, USA. Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr.
Reddy’s”) announced today that it has entered into a definitive agreement to acquire a portfolio of 42
approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the U.S.
The portfolio includes more than 30 generic injectable products. These products will require to be
technology transferred and could be launched within the next one to two years. The value of total
addressable market for these products in the U.S. is approximately $645 million for the calendar year
ending in December 2018 according to IQVIA.
Erez Israeli, Chief Operating Officer of Dr. Reddy’s Laboratories, commented, “The acquisition is in line
with our stated strategy to significantly enhance our portfolio in our chosen growth markets. This
transaction will help augment our injectables product portfolio in the U.S. market and globally.”
RDY-0419-244
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services &
Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major
markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the
management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forwardlooking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”,
“potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ
materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets,
credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and
morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the
policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.
The company assumes no obligation to update any information contained herein.

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post